SK Biopharm Launches Epilepsy New Drug 'Xcopri' in U.S. Market
[Asia Economy Reporter Oh Ju-yeon] SK announced on the 12th that its subsidiary SK Biopharm has officially launched the epilepsy drug Xcopri (XCOPRI, generic name Cenobamate) independently developed in the U.S. market. The company stated, "The sales of Xcopri will be conducted by SK Biopharm's U.S. local subsidiary, SK Life Science, Inc."
Hot Picks Today
![About 100 Trillion Won at Stake... "Samsung Strike Is an Unprecedented Opportunity" as Prices Surge 20% [Taiwan Chip Column]](https://cwcontent.asiae.co.kr/asiaresize/93/2026051416263163580_1778743590.jpg)
About 100 Trillion Won at Stake... "Samsung Strike Is an Unprecedented Opportunity" as Prices Surge 20% [Taiwan Chip Column]
- "Heading for 2 Million Won": The Company the Securities Industry Says Not to Doubt [Weekend Money]
- "Envious of Korean Daily Life"...Foreign Tourists Line Up in Central Myeongdong from Early Morning [Reportage]
- "Anyone Who Visited the Room Salon, Come Forward"… Gangnam Police Station Launches Full Staff Investigation After New Scandal
- Did Samsung and SK hynix Rise Too Much?... Foreign Assets Grow Despite Selling [Weekend Money]
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
